La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Enanta Pharmaceuticals Gestion
Gestion contrôle des critères 2/4
Le PDG Enanta Pharmaceuticals' est Jay Luly, nommé en Jul2003, a un mandat de 21.08 ans. La rémunération annuelle totale est $ 7.86M, composée du salaire de 9.6% et des bonus 90.4%, y compris les actions et options de la société. détient directement 3.51% des actions de la société, d'une valeur de $ 9.08M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.6 ans et 7.8 ans.
Informations clés
Jay Luly
Directeur général
US$7.9m
Rémunération totale
| Pourcentage du salaire du PDG | 9.6% |
| Durée du mandat du directeur général | 21.1yrs |
| Propriété du PDG | 3.5% |
| Dur ée moyenne d'occupation des postes de direction | 3.6yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 7.8yrs |
Mises à jour récentes de la gestion
Recent updates
Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results
Aug 08
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%
Jul 24Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Jun 19Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
May 09Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth
Mar 05Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 12Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Aug 13We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed
Feb 24Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade
Feb 08Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term
Nov 25Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?
Oct 25Enanta starts mid-stage trial of EDP-938 for RSV infection
Oct 03Enanta Pharma FQ3 2022 Earnings Preview
Aug 07Enanta potential COVID drug shows safety in healthy people in early-stage trial
Jul 29Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?
Jul 04Enanta: Slow Drip
May 17Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Feb 04Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Nov 25Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$115m |
| Mar 31 2024 | n/a | n/a | -US$132m |
| Dec 31 2023 | n/a | n/a | -US$138m |
| Sep 30 2023 | US$8m | US$755k | -US$134m |
| Jun 30 2023 | n/a | n/a | -US$132m |
| Mar 31 2023 | n/a | n/a | -US$125m |
| Dec 31 2022 | n/a | n/a | -US$121m |
| Sep 30 2022 | US$7m | US$725k | -US$122m |
| Jun 30 2022 | n/a | n/a | -US$120m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$101m |
| Sep 30 2021 | US$5m | US$693k | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$74m |
| Dec 31 2020 | n/a | n/a | -US$58m |
| Sep 30 2020 | US$5m | US$667k | -US$36m |
| Jun 30 2020 | n/a | n/a | US$2m |
| Mar 31 2020 | n/a | n/a | US$24m |
| Dec 31 2019 | n/a | n/a | US$34m |
| Sep 30 2019 | US$4m | US$642k | US$46m |
| Jun 30 2019 | n/a | n/a | US$65m |
| Mar 31 2019 | n/a | n/a | US$78m |
| Dec 31 2018 | n/a | n/a | US$86m |
| Sep 30 2018 | US$4m | US$611k | US$72m |
| Jun 30 2018 | n/a | n/a | US$81m |
| Mar 31 2018 | n/a | n/a | US$52m |
| Dec 31 2017 | n/a | n/a | US$34m |
| Sep 30 2017 | US$4m | US$581k | US$18m |
Rémunération vs marché: La rémunération totale de Jay ($USD 7.86M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 1.54M ).
Rémunération et revenus: La rémunération de Jay a augmenté alors que l'entreprise n'est pas rentable.
PDG
Jay Luly (68 yo)
21.1yrs
Titularisation
US$7,856,698
Compensation
Dr. Jay R. Luly, Ph.D. has been the Chief Executive Officer, President and Director of Enanta Pharmaceuticals, Inc. since July 2003. Dr. Luly joined Enanta in July 2003. Previously he was employed at Oxfor...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 21.1yrs | US$7.86m | 3.51% $ 9.4m | |
| Chief Financial & Administrative Officer | 20.9yrs | US$2.85m | 0.35% $ 945.3k | |
| Senior VP of Research & Development and Chief Scientific Officer | 24.8yrs | US$2.97m | 1.66% $ 4.4m | |
| Consultant | less than a year | US$2.86m | 0.43% $ 1.1m | |
| Chief Business Officer | 3.6yrs | US$2.58m | 0.10% $ 275.4k | |
| Senior Director of Investor Relations & Corporate Communications | no data | pas de données | pas de données | |
| Chief Legal Officer | less than a year | pas de données | pas de données | |
| Chief Product Strategy Officer | 3.7yrs | US$2.10m | 0.071% $ 190.3k | |
| Senior VP & Chief Medical Officer | 2yrs | US$4.84m | 0.017% $ 44.6k |
3.6yrs
Durée moyenne de l'emploi
59.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de ENTA est considérée comme expérimentée (ancienneté moyenne 3.6 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 21.1yrs | US$7.86m | 3.51% $ 9.4m | |
| Independent Director | 4.2yrs | US$331.41k | 0% $ 0 | |
| Independent Non-Executive Chairman | 10.8yrs | US$353.91k | 0% $ 0 | |
| Independent Director | 13.2yrs | US$333.91k | 0.027% $ 73.2k | |
| Independent Director | 6.9yrs | US$326.41k | 0% $ 0 | |
| Independent Director | 3yrs | US$318.91k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$321.41k | 0% $ 0 |
7.8yrs
Durée moyenne de l'emploi
65yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de ENTA sont considérés comme expérimentés (ancienneté moyenne 7.8 ans).